TITLE

Dysplasia in Barrett's Esophagus: Limitations of Current Management Strategies

AUTHOR(S)
Spechler, Stuart Jon
PUB. DATE
April 2005
SOURCE
American Journal of Gastroenterology;Apr2005, Vol. 100 Issue 4, p927
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Dysplasia is a very imperfect biomarker for malignancy in Barrett's esophagus. Invasive cancer has been found in 30–40% of esophagi resected because preoperative endoscopic examinations had shown high-grade dysplasia. Reports on the natural history of this disorder are sometimes contradictory, but suggest that 10–30% of patients with high-grade dysplasia in Barrett's esophagus will develop a demonstrable malignancy within 5 yr of the initial diagnosis. Proposed management strategies for high-grade dysplasia include esophagectomy, endoscopic ablative therapies, endoscopic mucosal resection (EMR), and intensive endoscopic surveillance. Endoscopic ablative therapies and EMR may not be effective if neoplastic cells have invaded the submucosa or disseminated through mucosal lymphatic channels, and a number of studies suggest that the endoscopic therapies usually leave metaplastic or neoplastic epithelium with malignant potential behind. Limited data suggest that intensive endoscopic surveillance might be a reasonable approach for elderly or infirm patients, but some patients managed in this fashion have developed incurable esophageal cancers. The fundamental question of what is the appropriate length of follow-up for studies on dysplasia treatments has not been resolved. Although 5 yr might be considered the absolute minimum duration for a meaningful follow-up on dysplasia therapy, the follow-up duration in most studies is substantially less than 5 yr. Specific recommendations for management based on these considerations are proposed at the end of this report.(Am J Gastroenterol 2005;100:1-9)
ACCESSION #
16433587

 

Related Articles

  • BARRETT'S OESOPHAGUS: AND AUDIT OF SURVEILLANCE OVER A 15 YEAR PERIOD. Gladman, L.; Chapman, W.; Iqbal, T. H.; Cooper, B. T. // Gut;Apr2004 Supplement 3, Vol. 53, pA54 

    Published reports of endoscopic surveillance of patients with Barrett's oesophagus (BO) have concentrated on the development of dysplasia and adenocarcinoma. No studies have audited what happens to patients with BO with regard to entry into or continuation with endoscopic surveillance...

  • Barrett's Esophagus, High-Grade Dysplasia, and Early Adenocarcinoma: A Pathological Study. Cameron, Alan J.; Carpenter, Herschel A. // American Journal of Gastroenterology;Apr1997, Vol. 92 Issue 4, p586 

    Objectives: In Barrett's esophagus, early adenocarcinomas are often missed on endoscopic biopsy. We therefore examined the distribution and extent of dysplasia and carcinoma in the resected esophagus for comparison with the preoperative biopsy findings. Methods: Patients whose endoscopy showed...

  • Superficial Esophageal Carcinoma: A Clinicopathological Review of 59 Cases. Yoshinaka, Heiji; Shimazu, Hisaaki; Fukumoto, Toshitaka; Baba, Masamichi // American Journal of Gastroenterology;Oct1991, Vol. 86 Issue 10, p1413 

    During the period from 1975 to 1989, a total of 59 patients with superficial esophageal carcinoma (SEC) were operated on in our Surgical Clinic. Forty patients of the 59 (68%) had been treated during the previous 5 yr. Although 22 patients (37%) complained of slight esophageal symptoms, 12...

  • Progression or regression of barrett's esophagus–is it all in the eye of the beholder? Dekel, Roy; Wakelin, Donald E.; Wendel, Chris; Green, Colleen; Sampliner, Richard E.; Garewal, Harinder S.; Martinez, Patricia; Fass, Ronnie // American Journal of Gastroenterology;Dec2003, Vol. 98 Issue 12, p2612 

    Accurate measurements of Barrett's esophagus length are important in clinical follow-up as well as in studies of therapeutic intervention in Barrett's esophagus. Our aim was to evaluate both the inter- and intraobserver reliability in measuring Barrett's length during two consecutive endoscopies...

  • Novel perspectives of long non-coding RNAs in esophageal carcinoma. Chen-Yu Lin; Han-Mei Xu // Carcinogenesis;Nov2015, Vol. 36 Issue 11, p1255 

    Esophageal carcinoma (EC) is one of the most aggressive cancer types worldwide. However, the underlying genomic events of EC are not fully understood. It is becoming evident that long non-coding RNAs (lncRNAs) play vital roles in tumorgenesis, metastasis, prognosis and diagnosis. Accumulating...

  • Uncertain Benefit of Barrett's Esophagus Surveillance. Ebell, Mark // American Family Physician;1/1/2004, Vol. 69 Issue 1, p169 

    Highlights a study on the long-term endoscopic surveillance of patients with Barrett's esophagus. Clinical setting of the study; Study design; Discussion on the result of the study.

  • Atypical Regenerative Hyperplasia of the Esophagus in Endoscopic Biopsy. Arista-Nasr, Julián; Rivera, Irene; Martinez-Benitez, Braulio; Bornstein-Quevedo, Leticia; Orozco, Héctor; Lugo-Guevara, Yadira // Archives of Pathology & Laboratory Medicine;Jul2005, Vol. 129 Issue 7, p899 

    Context.—Atypical regeneration can mimic carcinoma in various epithelia. On endoscopic biopsies, atypical regenerative hyperplasia of the esophagus may show pleomorphism and atypia, simulating esophageal squamous cell carcinoma. Objective.—To establish the most useful histologic...

  • Squamous Mucosa Overlying Columnar Epithelium in Barrett's Esophagus in the Absence of Anti-Reflux Surgery. Sampliner, Richard E.; Steinbronn, Karen; Garewal, Harinder S.; Riddell, Robert H. // American Journal of Gastroenterology;May1988, Vol. 83 Issue 5, p510 

    Seven of 45 patients with Barrett's esophagus prospectively followed with yearly endoscopy had histological evidence of squamous mucosa overlying Barrett's epithelium. This histological finding has previously been identified as a rare sequela of anti-reflux surgery. All seven patients had...

  • Dysplasia and Risk of Further Neoplastic Progression in a Regional Veterans Administration Barrett's Cohort. Dulai, Gareth S.; Shekelle, Paul G.; Jensen, Dennis M.; Spiegel, Brennan M.R.; Chen, Jaime; Oh, David; Kahn, Katherine L. // American Journal of Gastroenterology;Apr2005, Vol. 100 Issue 4, p775 

    OJECTIVES: No published data are available on the risk of further neoplastic progression in Barrett's patients stratified by baseline dysplasia status. Our aims were to estimate and compare the risk of progression to high-grade dysplasia or cancer in groups of Barrett's patients stratified by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics